ArticleFrontiers in pharmacology2023
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective.Therapeutic innovation & regulatory science · 2026Pooled it
- Preferences for Advanced Therapy Medicinal Products: Understanding the Published Literature on the Value of Innovative Health Interventions.Inquiry : a journal of medical care organization, provision and financingPooled it
- Fracture healing: from molecular and cellular mechanisms to therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications.3 Biotech · 2026Review
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- From microtissues to macro solutions - The future of scalable and automated cartilage tissue engineering.Journal of orthopaedic translation · 2026Review
- The Landscape of Advanced Therapy Medicinal Products in Slovenian Transfusion Medicine: A Review of Past and Future Outlook.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China.Regenerative therapy · 2026Review
- Protecting organ donation and transplantation programmes from regulatory uncertainty: an urgent appeal to the European Parliament, Council and Commission.The Lancet regional health. Europe · 2026Article
- The complex price setting and reimbursement of non-industrial advanced therapy medicinal products.Health economics review · 2026Article
- The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.HemaSphere · 2026Article
- Mesenchymal stem cell and exosome-based therapies for degenerative disc disease: from mechanisms to clinical translation.Frontiers in cell and developmental biology · 2026Review
- Regulatory approach to manipulated organs in Europe: preserving human organs as non-commercial goods.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.Journal of pharmaceutical policy and practice · 2026Review
- Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands.Regenerative medicine · 2025Article
- Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.BMJ (Clinical research ed.) · 2025Article
- Beyond Reimbursement Status: Availability of Advanced Therapy Medicinal Products Across the European Union.Therapeutic innovation & regulatory science · 2025Article
- Impact of regulatory measures on the approval timelines of advanced therapy medicinal products by the European Medicines Agency.Frontiers in medicine · 2025Article
- Early access disparities in innovative therapies across the US, EU, China, and Japan.Frontiers in medicine · 2025Article
- A hierarchical and configurational analysis of Health Technology Assessment outcomes for cell and gene therapies.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.